What is latanoprost 0.005% ophthalmic solution used for?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Latanoprost 0.005% Ophthalmic Solution: Indication

Latanoprost 0.005% ophthalmic solution is used to lower elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. 1

Primary Indication

This medication treats two main conditions:

  • Open-angle glaucoma - a chronic progressive eye disease that damages the optic nerve and can lead to irreversible blindness if untreated
  • Ocular hypertension - elevated pressure inside the eye that increases risk of developing glaucoma

How It Works

Latanoprost is a prostaglandin analog that reduces intraocular pressure by increasing uveoscleral outflow (the drainage of fluid from the eye). 2 The medication begins lowering pressure approximately 3-4 hours after administration, with maximum effect reached at 8-12 hours. 1

Dosing and Administration

The standard dose is one drop in the affected eye(s) once daily in the evening. 1 Key administration points include:

  • Do not exceed once-daily dosing - more frequent administration may paradoxically decrease effectiveness or even elevate IOP 1
  • If using multiple eye drops, wait at least 5 minutes between medications 1
  • Remove contact lenses before administration; may reinsert after 15 minutes 1

Position in Treatment Guidelines

Prostaglandin analogs like latanoprost are the most frequently prescribed initial therapy for glaucoma because they are highly efficacious, well-tolerated, and require only once-daily dosing. 3 Among first-line medications, latanoprost ranks among the most effective agents, though bimatoprost shows slightly superior IOP reduction while latanoprost has the most favorable tolerability profile. 4

Efficacy Evidence

Clinical trials demonstrate that latanoprost 0.005% once daily:

  • Reduces diurnal IOP by 22-39% over 1-12 months of treatment 2
  • Is more effective than timolol 0.5% twice daily in most comparative studies 2
  • Shows equivalent efficacy to other prostaglandin analogs (bimatoprost, travoprost) 4
  • Provides superior IOP lowering compared to dorzolamide, brimonidine, or unoprostone 2

Common Side Effects to Anticipate

The most frequent adverse effects are ocular and generally mild to moderate:

  • Conjunctival hyperemia (eye redness) - 3-15% of patients 2
  • Iris pigmentation changes - gradual browning of the iris that may be permanent (2-9%) 1, 2
  • Eyelash changes - increased length, thickness, and pigmentation (usually reversible) 1
  • Eye pain and irritation - particularly in initial weeks 5

Important caveat: Unlike beta-blockers (like timolol), latanoprost produces minimal systemic cardiovascular or respiratory side effects, making it safer for patients with asthma, COPD, or cardiac conditions. 2

Preservative-Free Formulations

Preservative-free latanoprost formulations are available and offer advantages for patients with:

  • Ocular surface disease
  • Sensitivity to benzalkonium chloride (BAK)
  • Need for long-term therapy
  • Planned future glaucoma surgery

These formulations provide equivalent IOP-lowering efficacy with improved ocular surface tolerability. 5, 6, 7

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.